Clinical Efficacy and Safety of Guselkumab in the Treatment of Moderate-to-Severe Psoriasis in Korea
- Author:
Jun-Oh SHIN
1
;
Kyung-Nam BAE
;
Jin-Hwa SON
;
Kihyuk SHIN
;
Hoonsoo KIM
;
Hyunchang KO
;
Moon-Bum KIM
;
Byungsoo KIM
Author Information
1. Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
- Publication Type:Original Article
- From:Korean Journal of Dermatology
2022;60(9):559-565
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Guselkumab, a human immunoglobulin-G1λ monoclonal antibody, selectively blocks the interleukin-23-mediated signaling pathway. It has emerged as a promising treatment option for moderate-to-severe psoriasis. However, no studies have reported real-world clinical data on guselkumab in patients with psoriasis in Korea.
Objective:To investigate the effectiveness and safety of guselkumab in Korean patients with moderate to severe plaque psoriasis.
Methods:We retrospectively reviewed patients with moderate-to-severe psoriasis who were treated with guselkumab at Pusan National University Hospital (Busan and Yangsan) from January 2019 to May 2021. Fifty-six patients with psoriasis who were treated with guselkumab were included in the study. Patient demographics, psoriasis area and severity index (PASI) scores, investigator’s global assessment scores, and adverse events were assessed.
Results:The mean baseline PASI score (16.2±7.6) significantly decreased after 20 weeks of guselkumab treatment (p＜0.05). In total, 76.8%, 78.6%, and 88.1% of patients achieved a PASI90 response at 20, 28, and 52 weeks, respectively. Of 56 patients, 52 had a PASI90 response at the last follow-up visit. No serious adverse events were observed. Four patients (7.1%) experienced mild adverse events, such as injection site reaction, upper respiratory tract infection, and headache.
Conclusion:This study reconfirmed the efficacy and safety of guselkumab in Korean patients with moderateto-severe psoriasis.
